Quarterly report pursuant to Section 13 or 15(d)

Business (Tables)

v3.20.4
Business (Tables)
6 Months Ended
Dec. 31, 2020
Schedule Of Entities In Control [Abstract]  
Summary of entities in control
The consolidated financial statements of Benitec Biopharma Inc. are presented in United States dollars and consist of Benitec Biopharma Inc. and its wholly owned subsidiaries:
 
   
Principal place of
business/country of
incorporation
  
Ownership
Fiscal Year
2020
   
Ownership
Fiscal Year
2019
 
Benitec Biopharma Proprietary Limited (“BBL”)
  Australia      100     —    
Benitec Australia Proprietary Limited
  Australia      100     100
Benitec Limited
  United Kingdom      100     100
Benitec, Inc.
  USA      100     100
Benitec LLC
  USA      100     100
RNAi Therapeutics, Inc.
  USA      100     100
Tacere Therapeutics, Inc.
  USA      100     100